BioCentury | Jan 3, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2018

...Intelligence; BioCentury Archives Indication Target Description Company or Institution Notes Therapeutic targets Cancer Breast cancer Prolyl 4-hydroxylase...
BioCentury | Dec 12, 2018
Distillery Therapeutics

Cancer

...Next steps could include identifying and testing additional P4HA1 inhibitors in models of TNBC. TARGET/MARKER/PATHWAY: Prolyl 4-hydroxylase...
...26, 2018 doi:10.1038/s41467-018-06893-9 CONTACT: Ren Xu, University of Kentucky, Lexington, Ky. email: ren.xu2010@uky.edu Chris Lieu University of Kentucky Prolyl 4-hydroxylase...
BioCentury | Nov 12, 2007
Clinical News

FG-2216: Phase I data

...San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: FG-2216 Business: Hematology Molecular target: Prolyl 4-hydroxylase...
BioCentury | Nov 12, 2007
Clinical News

FG-4592: Preliminary Phase II data

...San Francisco. FibroGen Inc. , South San Francisco, Calif. Product: FG-4592 Business: Hematology Molecular target: Prolyl 4-hydroxylase...
BioCentury | May 14, 2007
Clinical News

FG-2216: Phase II data

...San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: FG-2216 Business: Hematology Molecular target: Prolyl 4-hydroxylase...
Items per page:
1 - 5 of 5